Guidelines for the treatment of HIV continue to list two nucleoside reverse transcriptase
inhibitors (NRTIs) as the backbone of an effective antiretroviral regimen. Depending
upon baseline viral load and the presence of the HLA-B*5701 allele, the backbone
combines tenofovir or abacavir with either emtricitabine or lamivudine